Pharvaris (NASDAQ:PHVS) Stock Rating Upgraded by Wall Street Zen

Pharvaris (NASDAQ:PHVS) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Other equities research analysts have also issued reports about the company. Bank of America increased their price target on Pharvaris from $27.00 to $30.00 and gave the stock a “neutral” rating in a research report on Thursday, December 4th. Guggenheim lifted their price objective on Pharvaris from $32.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Thursday, January 22nd. Royal Bank Of Canada initiated coverage on Pharvaris in a report on Monday, March 9th. They set an “outperform” rating and a $52.00 target price on the stock. Finally, Morgan Stanley raised their target price on Pharvaris from $37.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, December 4th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $41.70.

Pharvaris Stock Performance

Shares of Pharvaris stock opened at $27.35 on Friday. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of -8.52 and a beta of -2.78. The firm’s 50-day moving average price is $26.91 and its two-hundred day moving average price is $25.27. Pharvaris has a 1-year low of $11.51 and a 1-year high of $29.80.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PHVS. Seven Fleet Capital Management LP bought a new position in Pharvaris in the 4th quarter valued at $1,536,000. XTX Topco Ltd raised its position in shares of Pharvaris by 126.1% during the fourth quarter. XTX Topco Ltd now owns 18,568 shares of the company’s stock worth $515,000 after acquiring an additional 10,355 shares during the last quarter. Ikarian Capital LLC raised its position in shares of Pharvaris by 131.7% during the fourth quarter. Ikarian Capital LLC now owns 486,856 shares of the company’s stock worth $13,510,000 after acquiring an additional 276,691 shares during the last quarter. Virtus Investment Advisers LLC lifted its stake in shares of Pharvaris by 66.7% during the fourth quarter. Virtus Investment Advisers LLC now owns 11,011 shares of the company’s stock valued at $306,000 after acquiring an additional 4,407 shares during the period. Finally, SummitTX Capital L.P. acquired a new position in shares of Pharvaris during the fourth quarter valued at $634,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.